Afya reports Q2 EPS R$2.27 vs. R$2.29 last year

Reports Q2 revenue R$919.4M, or R$879.0M excluding acquisitions, vs. R$809.9M last year. Company management stated, “We are pleased to report that Afya (AFYA) continues to deliver strong operational and financial results…This quarter was marked by significant revenue growth and gross margin expansion in both our Undergraduate and Continuing Education segments, reflecting the steady expansion of our business and our ongoing commitment to operational excellence. We are also pleased to reaffirm that Afya remains on track to meet our full-year 2025 guidance, supported by disciplined execution and strong business fundamentals. Once again, we delivered a strong performance, closing the first half of 2025 with a notable increase in Adjusted EBITDA Margin, reaching 48.1%…With the closing of the acquisition of Funic, a campus that will begin its operation in the second half of 2025, we are pleased to reinforce our solid market position by expanding our undergraduate footprint into the metropolitan area of Belo Horizonte, capital of Minas Gerais. This acquisition adds 60 new medical seats, bringing Afya’s total number of approved medical seats to 3,653 as of today. our Board of Directors approved a new share repurchase program. This initiative authorizes the repurchase of up to 4M Class A shares…Our commitment to innovation and excellence drives us to keep enhancing the medical journey at every stage”.